Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
gptkb:Duchenne_muscular_dystrophy
rare diseases |
| gptkbp:foundedYear |
2008
|
| gptkbp:founder |
Jill C. Milne
Michael Jirousek Steven Shoelson |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Catabasis Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
edasalonexent
|
| gptkbp:renamed |
2021
Astria Therapeutics |
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CATB
|
| gptkbp:website |
https://www.catabasis.com/
|
| gptkbp:bfsParent |
gptkb:Lightstone_Ventures
gptkb:SV_Health_Investors |
| gptkbp:bfsLayer |
8
|